ReviewExploration of targeted anti-tumor therapy2022

A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors.

Vincenzo Raimondi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.